– Pivotal data from lead program, ADAIR, expected in second half 2021 – Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 – Novel…
Read More
PHILADELPHIA, PA, March 03, 2021 — Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed…
– Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 — Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”),…
PHILADELPHIA, PA, Feb. 12, 2021 — Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed…
PHILADELPHIA, PA, Feb. 09, 2021 — Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in…
